Orna Therapeutics to Acquire ReNAgade Therapeutics

Orna Therapeutics to Acquire ReNAgade Therapeutics

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
Critical industry insight and formidable strength across key practices.

On May 23, Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA®), announced its acquisition of ReNAgade Therapeutics, a pioneer in unlocking the potential of RNA therapeutics that demonstrated industry-leading delivery to multiple extra-hepatic cells in non-human primate (NHP) models over the past 18 months. The partnership will combine Orna and ReNAgade’s technological capabilities to drive R&D that is uniquely focused on circular RNA therapeutics.

The WilmerHale team advising Orna Therapeutics was led by Rosemary Reilly and Mark Nylen, and included Rebecca Nauta, Joe Odegaard, Nick Andreacchi, Bill Caporizzo, Meghan Walsh, Amy Null, Jenna Ventorino and Senior Paralegal Cindy Sullivan. 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel